+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 39 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
L

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the long-term effects of aleniglipron, an oral drug, in adults living with obesity or overweight and type 2 diabetes mellitus T2DM. This randomized, double-blind, placebo-controlled phase 3 study aims to assess the efficacy, safety, and tolerability of multiple doses of aleniglipron for chronic weight management in this population. Participants will be randomly assigned to receive either oral aleniglipron or a placebo once daily. The treatment period lasts for 76 weeks, during which participants will take the assigned medication regularly. The study includes several experimental arms receiving aleniglipron and one placebo arm to compare outcomes. During the study, participants will have assessments at baseline and week 76 to measure changes in body weight, waist circumference, HbA1c levels, blood pressure, triglycerides, and cholesterol. Researchers will track the percentage of participants achieving significant weight loss and HbA1c targets. Safety and tolerability will be monitored throughout the treatment period, with the total participation lasting approximately 76 weeks.

Age: 18Years - 79YearsAll GendersPhase 3
74 locations
T

Actively Recruiting

Researchers are evaluating whether an anesthetic called Lidocaine may be effective when injected around the sciatic nerve of the intact limb in patients experiencing pain in the opposite limb after limb loss. This study focuses on people with phantom limb pain or residual limb pain who have undergone lower extremity amputation more than a year ago. The trial is a double-blind, randomized controlled study to assess pain relief and functional improvement. Participants will be randomly assigned to receive either a 2% lidocaine injection or a saline placebo injection in the back of their residual limb. The study compares these two treatments to understand their effects on pain and function. The trial is scheduled to start in June 2024 and will monitor participants shortly after injection and for several days following treatment. During the study, participants will be assessed for changes in pain levels at baseline and 60 minutes after injection, as well as changes in functional ability and disability five days post-injection. Additional measurements include pressure-pain sensitivity and step counts five days after treatment. Researchers will closely monitor participants and collect data related to these outcomes to evaluate the impact of the injections over time.

Age: 18Years +All GendersPhase 4
1 location
R

Actively Recruiting

Researchers are evaluating a new medication called CX11 for people with type 2 diabetes who have not achieved good blood sugar control despite taking a steady dose of metformin, with or without an SGLT2 inhibitor, for at least 90 days. This phase 2 study involves multiple medical centers and aims to determine the effectiveness and safety of CX11 compared to placebo in adults aged 18 to 75 years with specific blood sugar and body weight criteria. Participants will be randomly assigned to one of six groups, each receiving either a different dose of CX11 tablets or a matching placebo once daily. The treatment period lasts 24 weeks, followed by a 2-week safety follow-up. Neither participants nor study staff will know which group the participant is in during the study, ensuring a double-blind design. Throughout the study, participants will undergo various assessments including blood sugar measurements like HbA1c and continuous glucose monitoring, body weight and blood pressure checks, and safety monitoring for adverse events. Blood samples will be taken at multiple time points to measure drug levels. The primary outcome is the change in HbA1c after 24 weeks of treatment. Total participation lasts approximately 26 weeks, including treatment and follow-up.

Age: 18Years - 75YearsAll GendersPhase 2
48 locations
L

Actively Recruiting

Researchers are investigating the long-term effectiveness, safety, and tolerability of once-daily oral ASC30 compared to a placebo in adults with obesity or overweight and type 2 diabetes mellitus T2DM. This Phase III, global, randomized, double-blind, placebo-controlled study seeks to understand how different maintenance doses of ASC30 impact these participants over time. Participants will be randomly assigned to receive one of three doses of oral ASC30 tablets or matching placebo tablets once daily. The study compares these groups to evaluate the effects of ASC30 on weight and metabolic health over a 72-week period. Treatment is administered daily by mouth throughout the study. During participation, individuals will undergo regular assessments including measurements of body weight, blood sugar control HbA1c and fasting glucose, blood pressure, cholesterol, triglycerides, insulin levels, waist circumference, and body mass index. The main outcome is the percent change in body weight from the start to week 72. Safety and tolerability will be closely monitored, and the entire study duration spans about 72 weeks from baseline to final evaluation.

Age: 18Years +All GendersPhase 3
135 locations
B

Actively Recruiting

Healthy Volunteer

This study evaluates the immediate and long-term effects of structured breathing exercises on mental health symptoms such as anxiety, depression, perceived stress, and sleep quality in healthcare professionals. The research aims to understand how breathing practices might support mental well-being and resilience in this population. Participants will engage in self-guided structured breathing sessions lasting 15, 30, or 36 minutes, tailored to their personal skill level. These sessions are designed to improve brain circulation and mental well-being. The study uses a single group design without a comparison group, focusing on this breathing intervention over a four-month period. Throughout the study, participants will use a mobile app to track adherence, engagement, and satisfaction with the breathing exercises. Researchers will assess feasibility through recruitment ease, retention rates, and intervention acceptability. Mental health outcomes and participant feedback will be collected at regular intervals during the four months of study participation.

Age: 18Years - 85YearsAll GendersPhase Not Applicable
4 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety of an investigational varicella vaccine VNS Vaccine compared to an approved varicella vaccine called Varivax. This study focuses on healthy children aged 12 to 15 months who have not had chickenpox or received any varicella vaccine before. The goal is to understand how well the new vaccine is tolerated in this young population. Participants will receive one dose of either the investigational varicella vaccine or the marketed Varivax vaccine, both given by injection under the skin. Along with the varicella vaccine, each child will also receive one dose each of measles, mumps, and rubella MMR vaccine, hepatitis A vaccine, and a pneumococcal conjugate vaccine PCV, which may be PCV 13, Vaxneuvance, or PCV 20, depending on availability and national recommendations. All vaccines are given on the first day of the study. During the study, parents will record any side effects their child experiences, particularly those related to the injection site or systemic symptoms like fever, for up to 43 days. Researchers will monitor any adverse events, including serious and medically attended events, for up to 181 days after vaccination. This helps assess the safety and tolerability of the investigational vaccine over a period of about six months.

Age: 12Months - 15MonthsAll GendersPhase 3
46 locations
E

Actively Recruiting

Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.

Age: 12Years +All GendersPhase 3
185 locations
E

Actively Recruiting

This research investigates the impact of a team-based kidney care program on adults who have survived moderate to severe acute kidney injury AKI after a hospital stay. The study aims to evaluate how this multidisciplinary approach affects patient-centered outcomes compared to usual care. The goal is to improve recovery and prevent complications after hospital discharge by providing tailored support based on individual risk. Participants are assigned to one of two groups. The intervention group receives risk-based kidney care before leaving the hospital, which may include education, referrals to primary care with medication reviews, or nephrologist-led care combined with remote monitoring for up to 90 days post-discharge. The usual care group receives standard education, laboratory tests, and clinical follow-up after discharge. This pragmatic trial compares these approaches to assess their effects on health outcomes. During the study, participants are monitored for hospital-free days over 90 days, 180 days, and one year. Researchers also track hospital readmissions, death, kidney function changes, recurrence of AKI, chronic kidney disease progression, and cardiovascular events. Follow-up evaluations include laboratory tests, medication reviews, and specialist consultations. The research spans up to one year to assess the long-term effects of the kidney care program on patient health and recovery.

Age: 18Years +All GendersPhase Not Applicable
3 locations

1-10 of 39

1